Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) saw strong trading volume on Monday . 1,862,940 shares were traded during mid-day trading, an increase of 715% from the previous session’s volume of 228,559 shares.The stock last traded at $3.55 and had previously closed at $3.53.
A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 18th. Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 7th. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 4th. Finally, Bank of America assumed coverage on shares of Foamix Pharmaceuticals in a research note on Wednesday, December 12th. They issued a “buy” rating and a $11.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Foamix Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $14.69.
The firm has a market cap of $191.61 million, a P/E ratio of -2.02 and a beta of 1.73.
In other news, Director Aharon Schwartz purchased 50,000 shares of the business’s stock in a transaction on Monday, November 26th. The stock was purchased at an average cost of $3.89 per share, with a total value of $194,500.00. Following the acquisition, the director now directly owns 50,000 shares in the company, valued at $194,500. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 8,479 shares of company stock valued at $33,078. Insiders own 3.30% of the company’s stock.
A number of large investors have recently made changes to their positions in FOMX. Connor Clark & Lunn Investment Management Ltd. bought a new position in Foamix Pharmaceuticals in the 3rd quarter valued at $166,000. Credit Suisse AG bought a new position in Foamix Pharmaceuticals in the 3rd quarter valued at $194,000. Trexquant Investment LP boosted its holdings in Foamix Pharmaceuticals by 205.6% in the 3rd quarter. Trexquant Investment LP now owns 34,950 shares of the specialty pharmaceutical company’s stock valued at $200,000 after purchasing an additional 23,515 shares during the period. Federated Investors Inc. PA bought a new position in Foamix Pharmaceuticals in the 3rd quarter valued at $287,000. Finally, ETF Managers Group LLC lifted its holdings in shares of Foamix Pharmaceuticals by 66.6% during the 4th quarter. ETF Managers Group LLC now owns 81,972 shares of the specialty pharmaceutical company’s stock worth $294,000 after acquiring an additional 32,773 shares during the last quarter. 62.68% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Foamix Pharmaceuticals (FOMX) Sees Strong Trading Volume” was originally published by Zolmax and is the sole property of of Zolmax. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://zolmax.com/investing/foamix-pharmaceuticals-fomx-sees-strong-trading-volume/2892436.html.
About Foamix Pharmaceuticals (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
Further Reading: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.